石药集团(01093):SYH2051联合伊立替康脂质体用于治疗晚期实体瘤的Ib/II期临床试验在中国首个研究中心正式启动

智通财经
Yesterday

智通财经APP讯,石药集团(01093)发布公告,集团开发的SYH2051联合伊立替康脂质体用于治疗晚期实体瘤的Ib/II期临床试验已在中国首个研究中心正式启动。

该产品是一款高选择性的共济失调-毛细血管扩张症突变基因蛋白激酶抑制剂,注册分类为化学药品1类。该产品选择性抑制细胞脱氧核糖核酸损伤修复系统核心成分ATM激酶活性,可阻止肿瘤细胞DNA损伤修复。

本次启动的临床试验为一项多中心、开放设计的Ib/II期临床试验,计划入组晚期实体瘤患者,旨在评估该产品联合伊立替康脂质体的安全性及有效性。目前,该临床试验的参与者招募和筛选工作正在积极推进中。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10